Patients tolerated AVN-101 well in a wide range of doses: no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-101 for treatment of generalized anxiety disorders later this year.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Contact:

Alena Ivachtchenko, MBA
Director of Business Development
Ph:1(786) 617-4449
E-Mail:alena.iva@avineuro.com;
av@avineuro.com, av@chemdiv.com

www.avineuro.com

Avineuro LLC announced completion of phase II pilot clinical study of AVN-211, a proprietary orally-bioavailable molecule of a 5-HT6 receptor antagonist. In a multicenter double-blind randomized placebo-controlled pilot study of efficacy and safety of AVN-211 for amplifying the effects of antipsychotic drugs in patients with schizophrenia in a condition of incomplete remission receiving stable antipsychotic therapy, 80 patients were randomized to receive 8 mg of AVN-211 or Placebo QD for 6 weeks (initial dose 4 mg of AVN-211 was prescribed QD for 1 week following dose ascending up to 8 mg QD for 5 weeks or equivalent Placebo). The drug was safe and well-tolerated, no serious adverse effects were reported. Although there were no statistically significant difference between the groups in primary efficacy endpoint, patients on atypical antipsychotics demonstrated the tendency of superiority over Placebo in mean reduction of PANSS General score and Positive scale score. These results support the assumption of AVN-211 mode of action and synergetic antipsychotic effect of 5-HT6 inhibitors in patients receiving atypical antipsychotics. Thus it has been suggested that AVN-211 should be further investigated specifically in larger population of schizophrenic patients in incomplete remission receiving stable antipsychotic therapy with atypical antipsychotics for demonstrating amplification of the antipsychotic effect.

Avineuro LLC plans to continue clinical trials AVN-211 as adjuvant therapy in patients with schizophrenia in partial remission and adjuvant therapy of symptomatic treatment in patients with mild-moderate Alzheimer’s disease.

Contact:
Alena Ivachtchenko, MBA
Director, Business Development
Avineuro Pharmaceuticals, Inc.
www.avineuro.com
ei@avineuro.com
1-786-617-4449

Avineuro LLC plans to continue clinical trials AVN-211 as adjuvant therapy in patients with schizophrenia in partial remission and adjuvant therapy of symptomatic treatment in patients with mild-moderate Alzheimer’s disease.

Contact:

Alena Ivachtchenko, MBA

Director, Business Development

Avineuro Pharmaceuticals, Inc.

www.avineuro.com

ei@avineuro.com

1-786-617-4449

Avineuro Pharmaceuticals, Inc. reported today positive top-line results from a Phase 2a clinical proof of concept trial to assess AVN-211 as an augmentation therapy to improve cognition in schizophrenia patients. In a double blind trial in 50 patients stabilized on an atypical antipsychotic therapy, AVN-211 met the protocol criteria for positive results on the primary efficacy outcome measures. AVN-211, administered orally in the dose of 4 mg QD, was well tolerated and no adverse events were observed.

About AVN-211:
AVN-211 is a novel highly selective 5-HT6 receptor antagonist discovered and optimized on the company’s drug discovery 5-HT6 platform.

About Cognition impairment in Schizophrenia:
Cognition impairment in patients with schizophrenia is recognized by many psychiatrists as the very core of the dysfunction in this disease making it extremely difficult for patients to work, study and maintain a social lifestyle.

About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Contact:
Alena Ivashchenko, MBA
Director of Business Development
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive
San Diego, CA 92121
Phone: 858-357-6627
ei@avineuro.com
www.avineuro.com

http://www.alz.org/icad/overview.asp

Attendee: Yan Lavrovsky, ylavrovsky@avineuro.com

To schedule a meeting please contact us at info@avineuro.com

BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities.

Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE^®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

http://www.ebdgroup.com/bes/index.htm

Presenter: Yan Lavrovsky, ylavrovsky@avineuro.com

To arrange a meeting with him please contact us at info@avineuro.com

San Diego, CA – February 1st, 2010 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase II clinical studies of AVN-101, a potent multi-target small molecule for treatment of Alzheimer’s disease and anxiety. In Phase I studies AVN-101 was well tolerated in a wide range of doses and no adverse events were observed. The compound demonstrated excellent exposure and half-life of more than 14 hours. Avineuro Pharmaceuticals, Inc. will present early clinical results with AVN-101at ICAD 2010 in July and an update on its entire CNS portfolio at Bio-Europe Spring 2010 in Barcelona in March.

About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Contact:
Yan Lavrovsky, M.D., Ph.D.
CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive
San Diego, CA 92121
Phone: (858) 436-1537
Fax: (858) 228-9798
E-mail: ylavrovsky@avineuro.com
www.avineuro.com

BIO-Europe is Europe’s largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry.

Attendees: Yan Lavrovsky, ylavrovsky@avineuro.com

To arrange a meeting with him please contact us at info@avineuro.com